216 related articles for article (PubMed ID: 27698932)
1. Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity.
Huang A; Zhang X; Zhou SL; Cao Y; Huang XW; Fan J; Yang XR; Zhou J
J Cancer; 2016; 7(13):1907-1914. PubMed ID: 27698932
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor DNA correlates with microvascular invasion and predicts tumor recurrence of hepatocellular carcinoma.
Wang J; Huang A; Wang YP; Yin Y; Fu PY; Zhang X; Zhou J
Ann Transl Med; 2020 Mar; 8(5):237. PubMed ID: 32309384
[TBL] [Abstract][Full Text] [Related]
3. Assessments of TP53 and CTNNB1 gene hotspot mutations in circulating tumour DNA of hepatitis B virus-induced hepatocellular carcinoma.
Kumar S; Nadda N; Quadri A; Kumar R; Paul S; Tanwar P; Gamanagatti S; Dash NR; Saraya A; Shalimar ; Nayak B
Front Genet; 2023; 14():1235260. PubMed ID: 37593116
[No Abstract] [Full Text] [Related]
4. Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinoma.
Ge Z; Helmijr JCA; Jansen MPHM; Boor PPC; Noordam L; Peppelenbosch M; Kwekkeboom J; Kraan J; Sprengers D
Transl Oncol; 2021 Jul; 14(7):101073. PubMed ID: 33915518
[TBL] [Abstract][Full Text] [Related]
5. Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients.
van Ginkel JH; Huibers MMH; van Es RJJ; de Bree R; Willems SM
BMC Cancer; 2017 Jun; 17(1):428. PubMed ID: 28629339
[TBL] [Abstract][Full Text] [Related]
6. Development of Highly Sensitive Digital Droplet PCR for Detection of cKIT Mutations in Circulating Free DNA That Mediate Resistance to TKI Treatment for Gastrointestinal Stromal Tumor (GIST).
Rassner M; Waldeck S; Follo M; Jilg S; Philipp U; Jolic M; Wehrle J; Jost PJ; Peschel C; Illert AL; Duyster J; Scherer F; von Bubnoff N
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982486
[TBL] [Abstract][Full Text] [Related]
7. Sensitive droplet digital PCR method for detection of
McEvoy AC; Calapre L; Pereira MR; Giardina T; Robinson C; Khattak MA; Meniawy TM; Pritchard AL; Hayward NK; Amanuel B; Millward M; Ziman M; Gray ES
Oncotarget; 2017 Oct; 8(45):78890-78900. PubMed ID: 29108273
[TBL] [Abstract][Full Text] [Related]
8. Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay.
Lyu N; Rajendran VK; Diefenbach RJ; Charles K; Clarke SJ; Engel A; ; Rizos H; Molloy MP; Wang Y
Nanotheranostics; 2020; 4(4):224-232. PubMed ID: 32923312
[TBL] [Abstract][Full Text] [Related]
9. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma.
Oversoe SK; Clement MS; Weber B; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J
BMC Cancer; 2021 Apr; 21(1):376. PubMed ID: 33827453
[TBL] [Abstract][Full Text] [Related]
10. Interlaboratory assessment of droplet digital PCR for quantification of BRAF V600E mutation using a novel DNA reference material.
Dong L; Wang X; Wang S; Du M; Niu C; Yang J; Li L; Zhang G; Fu B; Gao Y; Wang J
Talanta; 2020 Jan; 207():120293. PubMed ID: 31594564
[TBL] [Abstract][Full Text] [Related]
11. Highly Specific Droplet-Digital PCR Detection of Universally Methylated Circulating Tumor DNA in Endometrial Carcinoma.
Beinse G; Borghese B; Métairie M; Just PA; Poulet G; Garinet S; Parfait B; Didelot A; Bourreau C; Agueeff N; Lavollé A; Terris B; Chapron C; Goldwasser F; Leroy K; Blons H; Laurent-Puig P; Taly V; Alexandre J
Clin Chem; 2022 Jun; 68(6):782-793. PubMed ID: 35323926
[TBL] [Abstract][Full Text] [Related]
12. Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma.
Huang A; Zhao X; Yang XR; Li FQ; Zhou XL; Wu K; Zhang X; Sun QM; Cao Y; Zhu HM; Wang XD; Yang HM; Wang J; Tang ZY; Hou Y; Fan J; Zhou J
J Hepatol; 2017 Aug; 67(2):293-301. PubMed ID: 28323123
[TBL] [Abstract][Full Text] [Related]
13. Up-front mutation detection in circulating tumor DNA by droplet digital PCR has added diagnostic value in lung cancer.
Visser E; de Kock R; Genet S; Borne BVD; Soud MY; Belderbos H; Stege G; de Saegher M; 't Westeinde SV; Broeren M; Eduati F; Deiman B; Scharnhorst V
Transl Oncol; 2023 Jan; 27():101589. PubMed ID: 36413862
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.
Liao W; Yang H; Xu H; Wang Y; Ge P; Ren J; Xu W; Lu X; Sang X; Zhong S; Zhang H; Mao Y
Oncotarget; 2016 Jun; 7(26):40481-40490. PubMed ID: 27248174
[TBL] [Abstract][Full Text] [Related]
15. Liquid biopsy with droplet digital PCR targeted to specific mutations in plasma cell-free tumor DNA can detect ovarian cancer recurrence earlier than CA125.
Minato T; Ito S; Li B; Fujimori H; Mochizuki M; Yamaguchi K; Tamai K; Shimada M; Tokunaga H; Shigeta S; Sato I; Shima H; Yamada H; Yaegashi N; Yasuda J
Gynecol Oncol Rep; 2021 Nov; 38():100847. PubMed ID: 34557579
[TBL] [Abstract][Full Text] [Related]
16. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
Tzanikou E; Markou A; Politaki E; Koutsopoulos A; Psyrri A; Mavroudis D; Georgoulias V; Lianidou E
Mol Oncol; 2019 Dec; 13(12):2515-2530. PubMed ID: 31254443
[TBL] [Abstract][Full Text] [Related]
17. Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrence.
Gassa A; Fassunke J; Schueten S; Kuhlmann L; Scherer M; Qien J; Zhao Y; Michel M; Loeser H; Wolf J; Buettner R; Doerr F; Heldwein M; Hagmeyer L; Frank K; Merkelbach-Bruse S; Quaas A; Bruns C; Hekmat K; Weiss J; Wahlers T; Alakus H
Lung Cancer; 2021 Jan; 151():91-96. PubMed ID: 33257044
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.
Feng W; Jia N; Jiao H; Chen J; Chen Y; Zhang Y; Zhu M; Zhu C; Shen L; Long W
J Transl Med; 2021 Feb; 19(1):51. PubMed ID: 33536036
[TBL] [Abstract][Full Text] [Related]
19. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
[TBL] [Abstract][Full Text] [Related]
20. Somatic TP53 Mutations Are Detectable in Circulating Tumor DNA from Children with Anaplastic Wilms Tumors.
Treger TD; Chagtai T; Butcher R; Cresswell GD; Al-Saadi R; Brok J; Williams RD; Roberts C; Luscombe NM; Pritchard Jones K; Mifsud W
Transl Oncol; 2018 Dec; 11(6):1301-1306. PubMed ID: 30172241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
